| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 07/07/2011 | WO2010067007A3 Synthesis of morphine-6-glucuronide or one of the derivatives thereof |
| 07/07/2011 | US20110166231 Method of treating a human being for a class of metabolic defects and energy production disorders |
| 07/07/2011 | US20110166230 Method of treating a human being for a class of neurological defects and seizure disorders |
| 07/07/2011 | US20110166229 Prevention of psychotic disorders and/or treatment of psychotic symptoms |
| 07/07/2011 | US20110166218 Methods for micronization of hydrophobic drugs |
| 07/07/2011 | US20110166215 Methods of improving the pharmacokinetics of doxepin |
| 07/07/2011 | US20110166208 Nucleotide and Amino Acid Sequences for Calmodulin Protein Methyltransferase |
| 07/07/2011 | US20110166197 Antisense Modulation Of Amyloid Beta Protein Expression |
| 07/07/2011 | US20110166196 Treatment and prophylaxis of epilepsy and febrile seizures |
| 07/07/2011 | US20110166194 Asenapine Prodrugs |
| 07/07/2011 | US20110166189 Methods of using sustained release aminopyridine compositions |
| 07/07/2011 | US20110166188 Methods of using sustained release aminopyridine compositions |
| 07/07/2011 | US20110166187 Methods of using sustained release aminopyridine compositions |
| 07/07/2011 | US20110166185 Disease risk factors and methods of use |
| 07/07/2011 | US20110166181 Guanidine compounds as anesthetics and for treatment of nervous system disorders |
| 07/07/2011 | US20110166178 Methods for treating anemia using inhibitors of hypoxia-inducible factor (HIF) hydroxylase |
| 07/07/2011 | US20110166175 7-azaindole derivatives |
| 07/07/2011 | US20110166174 Compounds modulating c-kit and c-fms activity and uses therefor |
| 07/07/2011 | US20110166173 3,5-disubstututed 1h-pyrrolo [2,3-b] pyridines as jnk inhibitors |
| 07/07/2011 | US20110166169 Novel hsp90 inhibitory carbazole derivatives, compositions containing same and use thereof |
| 07/07/2011 | US20110166160 Pyrazinone Modulator of Corticotropin-Releasing Factor Receptor Activity |
| 07/07/2011 | US20110166159 Compounds that modulate intracellular calcium |
| 07/07/2011 | US20110166158 Substituted phenylamine carboxamide analogs as mglur5 negative allosteric modulators and methods of making and using the same |
| 07/07/2011 | US20110166156 Prodrugs for the Treatment of Schizophrenia and Bipolar Disease |
| 07/07/2011 | US20110166155 Substituted Isoindolones and Their Use as Metabotropic Glutamate Receptor Potentiators |
| 07/07/2011 | US20110166150 Anhydrous Crystal Form Of Ovrepitant Maleate |
| 07/07/2011 | US20110166146 IMIDAZO[1,2-a]PYRIDINE COMPOUNDS |
| 07/07/2011 | US20110166145 Stabilization of hypoxia inducible factor (HIF) alpha |
| 07/07/2011 | US20110166140 Novel sulphonylpyrroles |
| 07/07/2011 | US20110166138 Inhibitors of Fatty Acid Amide Hydrolase and Monoacylglycerol Lipase for Modulation of Cannabinoid Receptors |
| 07/07/2011 | US20110166136 Calcium Ion Channel Modulators & Uses Thereof |
| 07/07/2011 | US20110166135 Aromatic nitrogen-containing 6-membered ring compounds and their use |
| 07/07/2011 | US20110166133 Fused nitrogen containing heterocycles and compositions thereof as kinase inhibitors |
| 07/07/2011 | US20110166132 Gamma Secretase Modulators |
| 07/07/2011 | US20110166128 Diaryldiazepine Prodrugs for the Treatment of Neurological and Psychological Disorders |
| 07/07/2011 | US20110166125 Substituted amides, manufacturing and use thereof as medicaments |
| 07/07/2011 | US20110166122 SUBSTITUTED IMIDAZO[1,2b]PYRIDAZINE COMPOUNDS AS TRK KINASE INHIBITORS |
| 07/07/2011 | US20110166115 Use of mifepristone for the treatment of amyotrophic lateral sclerosis |
| 07/07/2011 | US20110166110 Fused Ring Azadecalin Glucocorticoid Receptor Modulators |
| 07/07/2011 | US20110166104 Boron-containing small molecules |
| 07/07/2011 | US20110166103 Boron-containing small molecules |
| 07/07/2011 | US20110166093 Use of adenosine receptor agonists in therapy |
| 07/07/2011 | US20110166085 Composition comprising carbohydrates and peptides which comprise tryptophan |
| 07/07/2011 | US20110166084 Controlled release composition and method of producing the same |
| 07/07/2011 | US20110166075 Method of treating degenerative disorders of the nervous system by administration of fibrinogen fragment |
| 07/07/2011 | US20110166074 Cln2 treatment of alzheimer's disease |
| 07/07/2011 | US20110165262 Reducing drug dependence or addiction |
| 07/07/2011 | US20110165253 Nicotine-containing granulate |
| 07/07/2011 | US20110165252 Memantine formulations |
| 07/07/2011 | US20110165251 Liquid dosage compositions of stable nanoparticulate active agents |
| 07/07/2011 | US20110165247 Device for the transdermal administration of a rotigotine base |
| 07/07/2011 | US20110165243 Concurrent delivery of multiple therapeutic agents via hydrogels for biomedical applications |
| 07/07/2011 | US20110165238 Stabilized atypical antipsychotic formulation |
| 07/07/2011 | US20110165235 Directly pressed aliskiren tablets |
| 07/07/2011 | US20110165233 Stability additives for dry dha dosage forms |
| 07/07/2011 | US20110165222 Transdermal compositions containing low molecular weight drugs which are liquid at room temperatures |
| 07/07/2011 | US20110165179 Therapeutic agents for alzheimer's disease and cancer |
| 07/07/2011 | US20110165146 Methods of diagnosing alzheimer's disease |
| 07/07/2011 | US20110165142 Method of treating degenerative diseases |
| 07/07/2011 | US20110165141 Compositions for treating bacterial infections |
| 07/07/2011 | US20110165131 Methods for treating diseases and increasing longevity |
| 07/07/2011 | US20110165129 Ameliorating Nervous Systems Disorders |
| 07/07/2011 | US20110165116 Pharmaceutical compositions comprising ccl2 and use of same for the treatment of inflammation |
| 07/07/2011 | US20110165114 Drug delivery composition |
| 07/07/2011 | US20110165066 Interleukin-13 binding proteins |
| 07/07/2011 | US20110165063 Il-1 binding proteins |
| 07/07/2011 | US20110162981 Methods and compositions for preventing, reducting or treating damage caused by ischemia and schemia-like conditions |
| 07/07/2011 | CA2786155A1 Diazoxide for use in the treatment of a central nervous system (cns) autoimmune demyelinating disease |
| 07/07/2011 | CA2785957A1 .alpha.4.beta.2 neuronal nicotinic acetylcholine receptor ligands |
| 07/07/2011 | CA2785714A1 Anaplerotic therapy for alzheimer's disease and the aging brain |
| 07/07/2011 | CA2785341A1 Pyrazine derivatives and their use in the treatment of neurological disorders |
| 07/07/2011 | CA2785237A1 Sulphated disaccharides for the treatment of neurodegenerative and/or neurovascular diseases |
| 07/07/2011 | CA2784768A1 Tetrahydrotriazolopyridine compounds as selective mglu5 receptor potentiators useful for the treatment of schizophrenia |
| 07/07/2011 | CA2784394A1 Depot systems comprising glatiramer or a pharmacologically acceptable salt thereof |
| 07/07/2011 | CA2784153A1 Novel (heterocycle/tetrahydropyridine)-(piperazinyl)-1-alcanone and (heterocycle/dihydropyrrolidine)-(piperazinyl)-1-alcanone derivatives, and use thereof as p75 inhibitors |
| 07/07/2011 | CA2784132A1 Composition for improving brain function and method for improving brain function |
| 07/06/2011 | EP2341348A1 Methods for detecting cross beta structure comprising proteins with crossbeta structure binding compounds. |
| 07/06/2011 | EP2341143A1 OX2 receptor homolog |
| 07/06/2011 | EP2341080A1 Humanized immunoglobulins and their production and use |
| 07/06/2011 | EP2341068A1 A method of detecting and/or identifying adeno-associated virus (AAV) sequences and isolating novel sequences identified thereby |
| 07/06/2011 | EP2341063A2 Novel immunogenic compositions for the prevention and treatment of meningococcal disease |
| 07/06/2011 | EP2341062A2 Novel immunogenic compositions for the prevention and treatment of meningococcal disease |
| 07/06/2011 | EP2341048A1 Thiazolium salt compound and the use of treating the protein aging disease |
| 07/06/2011 | EP2341047A1 Cyclohexane derivative and pharmaceutical use thereof |
| 07/06/2011 | EP2340872A1 New pharmaceutical formulations useful in the treatment of insomnia |
| 07/06/2011 | EP2340849A1 Anti-NGF antibodies for the treatment of various disorders |
| 07/06/2011 | EP2340835A1 Piperidine and piperazine derivatives |
| 07/06/2011 | EP2340833A2 Controlled release oxycodone compositions |
| 07/06/2011 | EP2340832A1 Morphinan-6-one compounds for the treatment or prevention of neurodegenerative diseases |
| 07/06/2011 | EP2340831A1 HT0712 for the treatment of a cognitive deficit |
| 07/06/2011 | EP2340828A1 Pharmaceutical combinations of an angiotensin receptor antagonist and an nep inhibitor |
| 07/06/2011 | EP2340827A2 Method and preparation preventing and/or treating neurodegenerative or neurological disorders using a drug combination |
| 07/06/2011 | EP2340826A2 Method and preparation preventing and/or treating neurodegenerative or neurological disorders |
| 07/06/2011 | EP2340825A2 Method and preparation preventing and/or treating neurodegenerative or neurological disorders using a neurotransmitter precursor |
| 07/06/2011 | EP2340824A2 Method and preparation for reducing the severity of ADHD and/or motor disorders |
| 07/06/2011 | EP2340819A1 Compositions comprising venlafaxine and celecoxib in the treatment of pain |
| 07/06/2011 | EP2340813A1 Solid dosage formulations of galantamine |
| 07/06/2011 | EP2340254A1 Compositions and methods for treating epilepsy |
| 07/06/2011 | EP2340248A2 Methods and compositions for modulating ire1, src, and abl activity |
| 07/06/2011 | EP2340247A1 Quinolizidinone m1 receptor positive allosteric modulators |